Article
Baseline Characteristics of the VANISH Cohort.
Circulation. Heart failure - 1 Dec 2019
Axelsson Raja Anna, Shi Ling, Day Sharlene M, Russell Mark, Zahka Kenneth, Lever Harry, Colan Steven D, Margossian Renee, Hall E Kevin, Becker Jason, Jefferies John Lynn, Patel Amit R, Choudhury Lubna, Murphy Anne M, Canter Charles, Bach Richard, Taylor Matthew, Mestroni Luisa, Wheeler Matthew T, Benson Lee, Owens Anjali T, Rossano Joseph, Lin Kimberly Y, Pahl Elfriede, Pereira Alexandre C, Bundgaard Henning, Lewis Gregory D, Vargas Jose D, Cirino Allison L, McMurray John J V, MacRae Calum A, Solomon Scott D, Orav E John, Braunwald Eugene, Ho Carolyn Y
Abstract excerpt
BACKGROUND: The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progression. We describe the baseline characteristics of the VANISH cohort and compare to previous trials evaluating angiotensin receptor blockers....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.